Therefore, combining an anti-angiogenic treatment such as bevacizumab (VEGF inhibitor) with vaccine seems a valid strategy to enhance the anti-cancer T cells (triggered by the vaccine) homing to tumor. The gene discussed is VEGFA; the disease is neoplasm.